PDA Points to Consider: Best Practices for Document/Data Management and Control and Preparing for Data Integrity Inspections

Deborah M. Autor, Zena Kaufman, Ron Tetzlaff, et al.

PDA Journal of Pharmaceutical Science and Technology 2018,
Access the most recent version at doi:10.5731/pdajpst.2018.008573
PDA Points to Consider: Best Practices for Document/Data Management and Control and Preparing for Data Integrity Inspections

Authors:
Deb Autor, Mylan
Zena Kaufman, Roivant Pharmaceuticals
Ron Tetzlaff, PAREXEL International
Maryann Gribbin, Faith and Royale Consultants
Madlene Dole, Novartis
Derek Glover, Mylan
Brad Mercer, Avantor Inc.
Doreen Newhouse, Bridge Associates International LLC
Jackie Veivia-Panter, Celgene
Anil Sawant, Merck
Denyse Baker, PDA

Corresponding Author:
Deb Autor
Head of Strategic Global Quality and Regulatory Policy
Mylan
deborah'autor@mylan.com
202-507-5345

Conflict of Interest Statement:
Authors declare no conflict of interest.

Abstract:
PDA has identified eleven current questions related to data management and control that have been frequently cited in FDA Inspections or have led to FDA regulatory actions. The purpose of this document is to help to clarify some of these issues for industry and to help facilitate better compliance by sharing PDA members’ expertise in and understanding of current best practices.

Data integrity inspectional observations by health authorities can have a severe impact on a firm from a regulatory and public perception perspective and should not result from a lack of clarity by industry about what is required. In addition, firms are concerned that the inability to produce a requested record or document during an inspection, even if not a standard report or existing quality system document, could be construed as delaying, denying, limiting, or refusing inspection, which also has significant consequences.

PDA acknowledges it may not be possible for a single firm or site to have a meaningful discussion of these issues in the context of an inspection or inspection response and is offering these best practices so
that industry can proactively comply and properly prioritize its efforts to improve document management and control and GMP in the most efficient and effective means possible. PDA acknowledges there are many more questions to be addressed and hopes that there can be an ongoing dialogue between industry and regulators to facilitate answers.
PDA Points to Consider: Best Practices for Document/Data Management and Control and Preparing for Data Integrity Inspections

Background and Purpose

Based on its own experience and through a broad industry survey conducted with support from the Association for Accessible Medicines (AAM) and the Pharma & Biopharma Outsourcing Association (PBOA), PDA has identified current questions related to data management and control that have been frequently cited in FDA inspections or have led to FDA regulatory actions. The PDA Data Integrity Task Force has selected eleven questions to address at this time and included recommended best practices for each situation. The purpose of this document is to help to clarify these issues for industry and to help facilitate better compliance by sharing PDA members’ expertise in and understanding of current best practices.

Data integrity inspectional observations by health authorities can have a severe impact on a firm from a regulatory and public perception perspective and should not result from a lack of clarity by industry about what is required. In addition, firms are concerned that the inability to produce a requested record or document during an inspection, even if not a standard report or existing quality system document, could be construed as delaying, denying, limiting, or refusing inspection, which also has significant consequences.

Question 1: Copies of GMP Records

Context: On a daily basis, there are many valid reasons why a firm may wish to make copies of GMP records, including records that contain a lot number, batch-specific data, test results, or other data. For example, firms may make a copy of a batch record to provide to a Technical Services group to conduct an investigation. Especially in light of recent 483 observations that highlight documents with batch information found in a shredder, it is unclear under what conditions it is permissible to treat copies of GMP records as uncontrolled, non-GMP records. Requiring that the issuance, management, and destruction of all of these documents be controlled by the Quality Unit imposes an unnecessary burden on industry. The key is for firms to be able to show how they assure that an original record is the original record and that the data in the record satisfy ALCOA principles.

Issue: Is a copy of a GMP record (e.g., printout of the raw data or photocopy/scan of a paper original record) itself considered a GMP document?

Clarification: As long as firms have full control over original GMP documents and the original GMP document is retained as required by the firm’s procedure, copies can be created and destroyed as needed. A copy of a GMP record need only be retained if additional GMP information (e.g., raw data) is
Question 2: Documents not traditionally considered GMP records

Context: In recent 483s, we have observed that documents not traditionally considered GMP records (e.g., e-mails and other communications) become the object of scrutiny and observations. A working definition of what the agency currently views as a GMP record for such things as e-mail, supervisor schedule, etc. would be helpful for industry. Firms communicate informally about production and quality-related activities on a continuing basis in order to facilitate operations. An e-mail regarding batch release may be essentially the written equivalent of a phone call from one colleague to another stating that a batch has been released. Requiring formal controls around all of these documents, or requiring that such documents cannot be printed and discarded/destroyed/shredded at will, creates a large burden on firms and their quality units.

Issue: Are e-mails or other papers that contain batch-related information such as product name, lot number, or test results considered GMP records if local procedures are clear on what is the system of record?

Clarification: Whether a document is considered a GMP record depends on whether it is generated to satisfy a GMP requirement (see Data Integrity and Compliance with CGMP, Guidance for Industry, April 2016 draft, “When generated to satisfy a CGMP requirement, all data become a CGMP record.”) For example, if e-mail is used as a record of batch release, it is a GMP document. If e-mail is used to communicate that a batch has been released, but the system of record for batch release is not e-mail, then the e-mail is not a GMP record. Similarly, drafts of risk assessments, investigation reports, etc. are not cGMP records until they have been reviewed and finalized. If companies use e-mails for GMP purposes, it is advisable to have a controlled process, governed by an SOP.

Question 3: Personal Diaries

Context: It is common for employees to use personal diaries or paper to record notes for themselves for non-GMP purposes e.g. to-do list, training notes, personnel information. These notes are not considered to be GMP records by industry in general. Turning these notes into GMP records may in fact deter individuals from writing down information that is useful for effective time management or reinforcing one’s own learning.

Issue: What types of entries/information can be recorded in a personal diary without it being considered GMP record?

Clarification: If notes and diaries are used as personal and informal means of recording and are not the system of record for execution or documentation of GMP activities, then they are not considered to be GMP records. These informal recordings in personal notebooks might include to-do lists, training notes, coaching ideas, personnel information, etc.). Firms may want to consider
controlling and spot checking personal notebooks to ensure that they are being used only for non-GMP information. Firms may also want to train employees on what is and is not proper for recording in personal notebooks.

**Question 4: Drafts of GMP documents**

**Context:** Firms generate many drafts of CGMP documents. It would be onerous and confusing to require that all of those documents be retained.

**Issue:** Are firms required to retain drafts of CGMP documents, such as reports of risk assessments, investigations, and validation?

**Clarification:** Once a final GMP document of record is created, drafts and documents used in the creation of the document of record no longer need to be retained. This includes documents and drafts used or created in the course of conducting an investigation. The final document is the document of record. GMP Change Control processes come into effect once a GMP document is formally approved. As a part of maintaining control over GMP documents, it is advisable to make sure that drafts can be readily distinguished from final documents (e.g., they are stamped as “draft”).

**Question 5: Emails as GMP records**

**Context:** Firms use e-mail for a variety of GMP and non-GMP purposes. It is unclear to many firms which uses constitute GMP uses and whether a firm’s entire e-mail system becomes a GMP system due to its use.

**Issue:** Are e-mails considered to be GMP records?

**Clarification:** Whether e-mails are GMP records depends on whether they are being used to communicate GMP actions or content or capture GMP decision-making.

For example, if e-mail is used as the system of record for batch release, then those e-mails are GMP records, and local procedures should be clear on what is the system of record. If e-mail is used to communicate that a batch has been dispositioned, but that decision is formally captured elsewhere in accordance with the firm’s SOPs, then the e-mail is not a GMP record. Similarly, if e-mail is used as the official system for escalation of quality issues per a firm’s SOPs, then those e-mails are GMP records. If e-mail is used for informational purposes to note that there has been an escalation, and there is a separate system of record for escalations, then the e-mail is not a GMP record. The use of e-mail in GMP process(es) should be well-described in the relevant SOP(s).

To create a GMP record that is separate from the e-mail system, and to avoid an e-mail system being used as a GMP system of record, a firm may wish to consider printing, signing/initialed, and dating all of the relevant e-mails that constitute a GMP record. All of this should be done in accordance with a written SOP.

**Question 6: Business records that are not GMP records**
Recent inspections have delved into business records that are not GMP records, such as footage from security cameras, drafts of GMP documents such as investigations, uncontrolled document copies, and security key card access systems. FDA may choose to inspect these items and may even use them as a means of finding GMP violations. However, the fact that records may be inspected should not mean that these items are GMP records. Otherwise, it would create an enormous burden on the Quality Unit to review and control new kinds of records.

**Issue:** If non-GMP records, such as footage from security cameras, drafts of GMP documents such as investigations, uncontrolled document copies, and security key card access systems are inspected, does that mean that they are considered to be GMP records?

**Clarification:** No. When generated to satisfy a CGMP requirement, all data become a CGMP record. But the fact that a non-GMP record may be subject to inspection or may be the source of an inspectional observation pertaining to a GMP issue does not turn it into a GMP record. However, if a system is intended to provide documented evidence of a GMP function or GMP result then it is a GMP system. For example, if a key card entry system is used beyond employee exit and entry and is used as a log to monitor time spent in an aseptic core for purposes of media fill compliance, then it is being used for GMP purposes and should be clearly defined as such by local procedure. However, if such a system is evaluated on an occasional retrospective basis as part of a GMP investigation to ensure that an employee did not over-stay in the aseptic core, then that does not mean it should be considered a GMP system. Of course, any documentation from that system that is part of an investigation should be kept (in paper or electronic form) as a part of the investigation.

**Question 7: Use of shredders**

**Context:** There is no GMP requirement prohibiting the placement or use of shredders in a facility. However, in light of recent observations relating to shredders and shredding, more guidance on shredders and document management would be helpful.

**Issue:** What restrictions pertain to the placement and use of shredders?

**Clarification:** There are no restrictions on the placement of shredders in a facility. However, due to the risk of unauthorized shredding of GMP records, it is recommended that firms prohibit shredders or other means of potential unauthorized document destruction in areas where GMP functions are performed. This especially includes those areas that create raw data, including production, warehouse, and laboratory areas, where the risk is more acute. It is acceptable to have shredders in areas that do not generate GMP records and/or documents, although procedural controls are advisable. These departments can include HR, finance, and other management areas.

With respect to use of shredders, non-GMP records can be destroyed through whatever means a firm decides, including shredding (as long as such destruction does not violate corporate document retention policies). GMP records can be destroyed only when they have passed their retention period or if a true copy is being retained in place of original records.

For purposes of preserving confidentiality, firms may choose to provide secure bins for documents that require destruction in areas where there are not shredders. If those bins are in or near a GMP area, it is
recommended that firms create procedures defining how destruction is accomplished. For example, Quality Unit review of bin contents may be appropriate in certain circumstances, such as during an audit or in cases of suspicion of inappropriate document or data management.

In a Research and Development department, there may be GMP and non-GMP studies. It is advisable to create procedures and controls to prevent unauthorized destruction of GMP records in R&D.

Similarly, there are no restrictions on placement of correction fluid (e.g., Wite-Out) and sticky notes such as Post-It Notes, but it is advisable to prohibit them in GMP areas.

**Question 8: Retention of closed circuit television (CCTV)**

**Context:** Firms are unclear what is required for retention of closed circuit television (CCTV) footage.

**Issue:** For how long does a firm need to retain CCTV footage?

**Clarification:** CCTV footage from cameras that do not serve a GMP purpose, such as security cameras, should be handled in accordance with applicable firm procedures and retention policies. In general, there is not a GMP requirement to use CCTV. If CCTV footage is serving a GMP purpose, such as for batch release, then the footage should be retained as GMP documentation because it is part of the raw data supporting the disposition of the batch. It is not a GMP requirement to record aseptic process simulation/media fills, nor is retention of such videos required, unless the video is used as the primary documentation of a GMP operation (activity) that is not documented by other means (such as significant activities that are not documented on the batch record or control records for the process simulation batch). Please note, however, that it is a cGMP expectation to make a video of a smoke study validation. This video is the raw data supporting the qualification of a controlled environment, and the video should be retained as a GMP record. Aspects of local data privacy requirements also need to be considered in defining local procedures.

**Question 9: Data capture capabilities**

**Context:** Many pieces of production and laboratory equipment have extensive data capture capabilities. Firms are unclear whether they can disable unnecessary functions and/or rely on alternate recordkeeping systems.

**Issue:** If a piece of production or laboratory equipment has electronic data storage capability, is a firm required to utilize that capability?

**Clarification:** If production or laboratory equipment captures data that is required under GMPs, it must be used unless there is a reliable and complete alternate paper or electronic documentation system in place that meets GMP requirements. Please note, however, that if electronic raw data is dynamic, then a fixed/static paper or electronic record may not constitute a complete copy of the original record because that record may be missing GMP-required data that is captured in the
electronic system. Also, if there is an electronic audit trail, it should not be turned off in
favor of a manual audit trail as a manual audit trail is necessarily less robust than an
automatic one.

If an automated data capture system is disabled, it is advisable to document a good faith rationale for
disabling the system. Firms should be prepared to defend the rationale during inspection if necessary,
including evidence that all data required by cGMP is captured and retained by alternate system(s) as
applicable.

If an electronic data capture system is not disabled and is not utilized for GMP purposes, firms’
procedures should clearly identify what system is used as the source of raw data and what system is not.
It is also recommended that firms review the non-disabled system’s data as a part of their procedures.
The reason for this is that any data that is captured may be inspected by FDA and could be the basis for
concerns about data integrity, for example in the case of discrepancies between data in the two
different systems.

**Question 10: Quality Plans**

**Context:** Firms may be reluctant to create and document quality plans (documentation of their
goals and timelines for quality system improvement) for fear of that plan being used as the source of
483 observations.

**Issue:** If a firm has a quality plan, will an FDA investigator use that plan as the basis for 483
observations?

**Clarification:** If a firm has a quality plan, an investigator may assess the sufficiency of that
plan and whether the plan is being fully and timely executed. The fact that a firm has a reasonable
quality plan in place may not prevent observations but can be evidence of a firm’s willingness to self-
identify and address issues. The adequacy of the firm’s plan and the progress that the firm has made in
executing the plan may be viewed by a regulator as a positive indicator of the firm’s status. Using a
firm’s quality plan as a roadmap for negative observations could create a disincentive to creation of such
plans. Regulators often encourage firms to proactively meet with them if the firm finds data integrity
deficiencies, rather than waiting for those issues to be part of an inspection.

**Question 11: Questioning investigator actions in the field**

**Context:** There is a diversity of FDA investigators in the field, and inspections can unfold in a
variety of ways. Some firms are unsure of what to do if they perceive that an investigator is acting
inappropriately or inspecting non-GMP records, documents, or facilities without cause.

**Issue:** If a firm believes that an FDA investigator is acting inappropriately or inspecting non-
GMP records, documents or facilities without an apparent cause, what should the firm do?

**Clarification:** The law defines FDA’s inspectional scope for a drug factory, warehouse,
establishment, or lab as including “all things therein (including records, files, papers, processes, controls,
and facilities) bearing on whether” drugs are adulterated or misbranded or otherwise prohibited by the
FD&C Act. The only explicit limits on FDA's inspectional authority are that it does not extend to financial data, sales data other than shipment data, pricing data, personnel data (other than data as to qualification of technical and professional personnel performing functions subject to inspection), and research data that is beyond the scope of FDA requirements. (See FD&C Act 704.)

Firms should be aware, however, that FDA interprets its inspectional authority broadly. As FDA has stated, the law “authorizes FDA to conduct inspections at reasonable times, within reasonable limits, and in a reasonable manner. Although the [law] does not specifically define ‘reasonable,’ FDA has long maintained that the inspectional authority...‘extends to what is reasonably necessary to achieve the objective of the inspection.” (See Guidance for Industry, Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection (Oct. 2014). In 2012 the Food and Drug Administration Safety and Innovation Act (FDASIA), Public Law 112-144, was enacted. This law includes a provision that deems a drug to be “adulterated” if the drug “has been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator, or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.” Under this law, drug manufacturers that delay, deny, limit, or refuse to permit entry or inspection are potentially subject to regulatory sanctions by FDA including Import Alert, Warning Letter, and Seizure.

One issue that arises is what FDA can inspect, such as whether FDA can inspect the firm’s e-mail system, phone messages, and individuals’ offices. It has also been reported that FDA investigators have requested information or data in a format other than that which is generally used or maintained by the firm, and informed the firm that it would be a refusal of inspection if the firm does not produce the requested information or data in that format.

If a firm believes that an investigator is acting inappropriately or inspecting non-GMP records, documents, or facilities without an apparent cause, the first step is to raise that issue with the investigator. If the firm does not feel it can do so, or that effort is unsuccessful, the firm can contact the District Office at which the investigator works, the ORA ombudsman, or others in ORA or Center management to discuss the issue.

Conclusion:

PDA acknowledges that it may not be possible for a single firm or site to have a meaningful discussion of these issues in the context of an inspection or inspection response and is offering these best practices so that industry can proactively comply and properly prioritize its efforts to improve document management and control and GMP in the most efficient and effective means possible. PDA acknowledges there are many more questions to be addressed and hopes that there can be an ongoing dialogue between industry and regulators to facilitate answers.
An Authorized User of the electronic PDA Journal of Pharmaceutical Science and Technology (the PDA Journal) is a PDA Member in good standing. Authorized Users are permitted to do the following:

- Search and view the content of the PDA Journal
- Download a single article for the individual use of an Authorized User
- Assemble and distribute links that point to the PDA Journal
- Print individual articles from the PDA Journal for the individual use of an Authorized User
- Make a reasonable number of photocopies of a printed article for the individual use of an Authorized User or for the use by or distribution to other Authorized Users

Authorized Users are not permitted to do the following:

- Except as mentioned above, allow anyone other than an Authorized User to use or access the PDA Journal
- Display or otherwise make any information from the PDA Journal available to anyone other than an Authorized User
- Post articles from the PDA Journal on Web sites, either available on the Internet or an Intranet, or in any form of online publications
- Transmit electronically, via e-mail or any other file transfer protocols, any portion of the PDA Journal
- Create a searchable archive of any portion of the PDA Journal
- Use robots or intelligent agents to access, search and/or systematically download any portion of the PDA Journal
- Sell, re-sell, rent, lease, license, sublicense, assign or otherwise transfer the use of the PDA Journal or its content
- Use or copy the PDA Journal for document delivery, fee-for-service use, or bulk reproduction or distribution of materials in any form, or any substantially similar commercial purpose
- Alter, modify, repackage or adapt any portion of the PDA Journal
- Make any edits or derivative works with respect to any portion of the PDA Journal including any text or graphics
- Delete or remove in any form or format, including on a printed article or photocopy, any copyright information or notice contained in the PDA Journal